Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
Top Page
RenovoRx
(NASDAQ:RNXT)
Select Model
Select Model
Rating:49Neutral
Price Target:―
RenovoRx's overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company's valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.
Positive Factors
Innovative Therapy Platform
The proprietary RenovoTAMP platform offers a competitive advantage by enhancing chemotherapy efficacy and reducing side effects, potentially increasing adoption and partnerships in oncology.
Partnership Opportunities
Collaborations can lead to milestone payments and royalties, providing a diversified revenue stream and enhancing the company's financial stability over time.
Equity Improvement
Improved equity indicates better asset management and financial health, potentially increasing investor confidence and reducing reliance on debt.
Negative Factors
Negative Cash Flow
Persistent negative cash flow reflects operational challenges and reliance on external financing, posing risks to long-term sustainability and financial flexibility.
Profitability Challenges
Significant operational losses highlight ongoing profitability issues, limiting the company's ability to reinvest in growth and innovation.
Financial Instability
The company's fragile financial position, marked by persistent losses, undermines its ability to withstand economic fluctuations and invest in future growth initiatives.
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.24M
Dividend YieldN/A
Average Volume (3M)650.58K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth38.12%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,645,885
10 Day Avg. Volume752,967
30 Day Avg. Volume650,578
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue54.45
Enterprise Value/Gross Profit86.64
Enterprise Value/Ebitda-3.14
Forecast
1Y Price Target
$6.33Price Target Upside436.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
RenovoRx Business Overview & Revenue Model
Company DescriptionRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
How the Company Makes MoneyRenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.
RenovoRx Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant achievements in commercial sales and clinical trial progress, despite challenges in sales infrastructure and ongoing R&D expenses.Q2-2025 Updates
Positive Updates
Commercialization Success
RenovoRx achieved over $400,000 in sales in Q2 2025 without a dedicated sales and marketing team, highlighting strong market demand for the RenovoCath device.
Positive Interim Analysis for TIGR PACT Trial
The independent Data Monitoring Committee (DMC) recommended the continuation of the Phase III TIGR PACT trial, indicating confidence in a potential positive outcome.
Strong Financial Position
RenovoRx ended the quarter with $12.3 million in cash and cash equivalents, sufficient to fund ongoing commercial and clinical activities.
Panther Registry Study Launch
RenovoRx launched the Panther study to evaluate the real-world safety and effectiveness of RenovoCath in solid tumors, marking a significant step in understanding the device's long-term potential.
Market Expansion Potential
RenovoRx estimates a $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with potential expansion into a several billion dollar market for additional cancer applications.
Negative Updates
Research and Development Expenses
R&D expenses were $1.4 million for Q2 2025, reflecting a decrease from the previous year but still representing a significant cost.
Limited Sales Infrastructure
RenovoRx is still in the early stages of building a sales and marketing team, which may affect the pace of revenue growth and market penetration.
Company Guidance
During the RenovoRx second quarter 2025 conference call, the company provided several key metrics and updates. The RenovoCath device achieved over $400,000 in sales during the second quarter, marking significant early progress without a dedicated sales and marketing team. Ninety-five patients have been randomized in the Phase III TIGR PACT trial, with sixty-one events recorded, aiming to complete enrollment by late 2025 or early 2026. The company reported a revenue of approximately $422,000 for the quarter ending June 30, 2025, with research and development expenses at $1.4 million, reflecting a $100,000 decrease year-over-year. The company ended the quarter with $12.3 million in cash and cash equivalents. Looking ahead, RenovoRx estimates a total addressable market for RenovoCath as a standalone device of $400 million annually in the U.S., with potential expansion into a multi-billion dollar market as they explore additional cancer indications. The company's commercial strategy and clinical progress, including the positive recommendation from the DMC to continue the TIGR PACT trial, highlight a promising trajectory for RenovoRx in the oncology field.RenovoRx Financial Statement Overview
Summary
RenovoRx is facing significant financial challenges, with persistent losses and negative cash flows. Despite improvements in revenue and equity, the company's core operations remain unprofitable, and it heavily relies on external financing. The balance sheet shows some asset management improvements, but the overall financial health is fragile, with high operational losses posing a significant risk.Income Statement
RenovoRx shows a slight improvement in revenue with $43,000 reported in the latest year. However, the company faces a challenging profitability situation with a negative net income of $8.8 million and negative EBIT and EBITDA margins, indicating significant operational losses. The gross profit margin is also concerning as it demonstrates no cost of goods sold, which reflects no substantial revenue activities.30
Negative
Balance Sheet
The balance sheet highlights a modest improvement in stockholders' equity, now at $4.48 million, up from a negative position. However, the company maintains a high leverage with a debt-to-equity ratio of 0.05, which could be considered low in relative terms but is risky in the context of negative profitability. The equity ratio is positive, indicating a shift towards better asset management, but overall financial stability remains a concern.40
Negative
Cash Flow
Operating cash flow remains negative at $9.13 million, showing consistent cash outflows from operations. Free cash flow is similarly negative, reflecting the company's reliance on financing activities to sustain operations. This cash flow instability poses a risk to long-term sustainability, despite substantial financing inflows in the past year.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 662.00K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 416.00K | 43.00K | 0.00 | -6.00K | -9.00K | 0.00 |
| EBITDA | -11.49M | -10.97M | -11.39M | -9.94M | -5.66M | 0.00 |
| Net Income | -10.66M | -8.81M | -10.23M | -9.77M | -7.10M | -4.38M |
Balance Sheet | ||||||
| Total Assets | 13.64M | 8.12M | 1.47M | 7.26M | 16.29M | 1.91M |
| Cash, Cash Equivalents and Short-Term Investments | 12.31M | 7.15M | 1.17M | 6.44M | 15.19M | 1.79M |
| Total Debt | 260.00K | 278.00K | 0.00 | 0.00 | 0.00 | 2.79M |
| Total Liabilities | 3.00M | 3.64M | 4.47M | 1.10M | 938.00K | 16.57M |
| Stockholders Equity | 10.64M | 4.48M | -3.00M | 6.16M | 15.35M | -14.66M |
Cash Flow | ||||||
| Free Cash Flow | -10.32M | -9.14M | -10.26M | -8.81M | -5.93M | -3.53M |
| Operating Cash Flow | -10.31M | -9.13M | -10.26M | -8.81M | -5.92M | -3.53M |
| Investing Cash Flow | -14.00K | -12.00K | 2.03M | -2.03M | -15.00K | 0.00 |
| Financing Cash Flow | 10.89M | 15.12M | 5.01M | 42.00K | 19.33M | 3.20M |
RenovoRx Technical Analysis
Neutral
1.18
Price Trends
1.16
Positive
1.22
Negative
1.17
Positive
Market Momentum
0.03
Positive
49.58
Neutral
5.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Neutral. The current price of 1.18 is below the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.16, and above the 200-day MA of 1.17, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 49.58 is Neutral, neither overbought nor oversold. The STOCH value of 5.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 67 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RenovoRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $43.24M | ― | -107.11% | ― | ― | 38.12% | |
43 Neutral | $99.07M | -0.83 | ― | ― | ― | 35.81% | |
39 Underperform | $41.65M | -0.64 | ― | ― | ― | 3.39% | |
39 Underperform | $100.14M | -0.85 | ― | ― | ― | 39.60% | |
38 Underperform | $27.79M | -0.44 | ― | ― | ― | 17.02% | |
38 Underperform | $63.14M | -4.91 | ― | ― | ― | 41.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
RNXT
RenovoRx
1.18
0.12
11.32%
OVID
Ovid Therapeutics
1.73
0.55
46.61%
GRCE
Grace Therapeutics
3.09
0.09
3.00%
JSPR
Jasper Therapeutics
2.47
-16.34
-86.87%
NRSN
Neurosense Therapeutics Ltd.
1.24
-0.03
-2.36%
PEPG
PepGen Inc.
5.07
-3.48
-40.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.